[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Abu Dhabi Health Services Company\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":155},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,61,102,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100594116","assessing-the-burden-of-respiratory-syncytial-virus-rsv-100594116",false,"NCT07015255","Assessing the Burden of Respiratory Syncytial Virus (RSV)","Assessing the Burden of Respiratory Syncytial Virus (RSV): the Assessment of the Burden of Respiratory Syncytial Virus (RSV) Across Different Age Groups and Risk Factors","Inclusion Criteria:\n\n* Patients of all ages with a confirmed diagnosis of RSV infection\n* Patients admitted to a SEHA hospital or healthcare facility between January 2018 and December 2024\n* Patients with documented data in the SEHA electronic medical record (EMR) system\n\nExclusion Criteria:\n\n* Patients with suspected RSV infection that is not laboratory-confirmed\n* Patients without sufficient data in the SEHA EMR system","ALL",{"count":18,"type":19},1500,"ESTIMATED","OBSERVATIONAL","This study examines the impact of Respiratory Syncytial Virus (RSV) on people of all ages, from infants to the elderly. It uses hospital records collected between January 2018 and December 2024 to understand:\n\n* How often does RSV occur\n* Who is most at risk\n* The long-term and financial effects of RSV",[23,24,25,26,27],"Respiratory Syncytial Virus (RSV) Infection","Acute Lower Respiratory Tract Infections","Bronchiolitis","Pneumonia","Chronic Respiratory Conditions",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,25,26,45,46,47],"Respiratory Syncytial Virus","RSV","RSV Infection","RSV in Infants","RSV in Adults","RSV Hospitalization","RSV Epidemiology","RSV Burden","RSV Risk Factors","Retrospective Study","Observational Study","ICU Admissions","RSV Mortality","RSV Cost Analysis","RSV Complications","Asthma and RSV","Recurrent Wheezing","RSV Surveillance","RSV-Related Comorbidities","NOT_YET_RECRUITING","2025-06-17",{"date":51,"type":52},"2025-06-19","ACTUAL",{"date":54,"type":19},"2025-06",{"date":56,"type":19},"2026-06",{"name":58,"class":59},"Abu Dhabi Health Services Company","OTHER_GOV",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":60},"100557240","integrating-whole-genome-sequencing-and-digital-twins-into-the-management-of-hypercholesterolemia-in-emiratis-100557240","NCT06535542","Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in Emiratis","A Randomized Trial of Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in Emiratis","Inclusion Criteria:\n\n* Patients with 2 or more LDL-C levels greater than 190 mg\u002FdL or 5.0 mmol\u002FL in the past 12 months\n* Undiagnosed patients meeting Possible, Probable or Definitive FH criteria according to Dutch Lipid Clinic Network (DLCN) criteria (Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093\u002Feurheartj\u002Fehr158. Epub 2011 Jun 28.)\n* Patients who have not been on anti-lipidemic medication in the past 3 months\n* Ages 18-55\n* Emirati national\n* All patients must be fluent in English or Arabic\n\nExclusion Criteria:\n\n* \\- Patients who do not meet the above criteria\n* Patients with a previous diagnosis of FH\n* Patients with a progressive debilitating illness\n* Patient with untreated hypothyroidism, history of proteinuria, obstructive liver disease, chronic renal failure, human immunodeficiency virus infection, or on immunosuppressant or steroid or psychiatric medications\n* Patients with untreated clinical anxiety or depression (as measured by a Hospital Anxiety and Depression Scale (HADS) score of ≥ 16 on the depression subscale)\n* Patients who are pregnant","18 Years","55 Years",{"count":71,"type":19},40,"INTERVENTIONAL",[74],"NA","This pilot study investigates integrating whole genome sequencing and digital twin technology for managing hypercholesterolemia in Abu Dhabi clinics. It aims to establish protocols for larger future studies and incorporate genomic insights into routine medical care.",[77,78,79],"Hypercholesterolemia, Autosomal Dominant","Hypercholesterolemia, Autosomal Recessive","Familial Combined Hypercholesterolemia",[81,82,83,84,85,86,87,88,89,90,91,92],"LDH","Familial Hypercholesterolemia","Whole Genome Sequencing","Digital Twins","Management of Hypercholesterolemia","Emirati","Randomized Controlled Trial","Sanger Sequencing","Predictiv Care","Genomic Medicine","Precision Medicine","Pharmacogenomics","RECRUITING","2025-03-24",{"date":96,"type":52},"2025-03-25",{"date":98,"type":52},"2024-07-29",{"date":100,"type":19},"2026-07-15",{"name":58,"class":59},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":72,"phases":111,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":60},"100580354","phase-1-the-effect-of-gum-arabic-ga-on-residual-renal-function-in-adult-dialysis-patients-in-abu-dhabi-100580354","NCT06836206","The Effect of Gum Arabic (GA) on Residual Renal Function in Adult Dialysis Patients in Abu Dhabi","The Effect of Gum Arabic (GA) on Adult Dialysis Patients in Abu Dhabi: A Prospective Randomized-controlled Trial (The GADAD Study)","GAESRD","Inclusion Criteria:\n\nTo be eligible to participate in this trial, an individual must meet all the following criteria:\n\n1. Men and women ≥18 years of age with diagnosed ESRD and prescribed regular dialysis at least once a week, weekly at least for past two weeks.\n2. For past two weeks including women of childbearing potential who are currently adopting any method of contraception or have completed the family and undergone sterilization procedures and women of non-childbearing potential.\n3. Patients with residual renal function - Patients who produce a minimum of 200 ml of urine during a full day of collection (A full day collection: the patient discards the first urine sample on the day of collection then collects all urine for the entire day and night and collects the first urine sample of the next day) r on a non-dialysis long break day.\n4. Able and willing to complete the whole period of the study (maximum of 266 days from enrolment).\n5. With the ability to understand the study procedures, the informed consent \\& voluntarily sign an informed consent form and be able to comply with the requirements of the protocol.\n\nExclusion Criteria:\n\n1. Women of childbearing potential not adopting any methods of contraception, have not undergone sterilization.\n2. Women Pregnant or lactating\n3. Patients who plan to conceive (or for their partners to conceive) within 12 months of randomization.\n4. Patient presenting with serum K+levels ≥ 6mmol\u002FL based on the last two reports as per medical records.\n5. Patients who produce less than 200 ml of urine during 24 hours urine collection at baseline assessment.\n6. Peritoneal dialysis.\n7. Kidney transplant or booked for a live transplant within 259 days of randomization.\n8. Patients gaining \\>4 kg between dialysis sessions in the past 2 weeks.\n9. People with known allergies to quillaja bark or similar tree bark.\n10. Patients are already participating in another clinical trial (excluding COVID-19 vaccine or COVID-19 drug trials).\n11. Patients on immunosuppression for kidney transplant.\n\nAdditional exclusion criteria for follow-up visits.\n\n1. Patient informs of pregnancy.\n2. Severe adverse reaction to the interventional product.",{"count":71,"type":19},[112,113],"PHASE1","PHASE2","Gum Arabic (GA), derived from Acacia trees, has shown potential benefits in metabolic, renal, and inflammatory conditions. This study explores the impact of GA on residual renal function in end-stage renal disease (ESRD) patients undergoing dialysis, as current evidence is limited.",[116],"End Stage Renal Disease (ESRD)",[118,119,120],"Gum Arabic","ESRD","Acacia seyal and Acacia senegal","2025-02-14",{"date":123,"type":52},"2025-02-20",{"date":125,"type":52},"2025-02-03",{"date":127,"type":19},"2026-04-30",{"name":58,"class":59},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100557237","clinical-characteristics-and-outcomes-among-stemi-patients-with-cardiogenic-shock-at-abu-dhabi-city-100557237","NCT06535503","Clinical Characteristics and Outcomes Among STEMI Patients With Cardiogenic Shock at Abu Dhabi City","Clinical Characteristics and Outcomes Among ST-elevation Myocardial Infarction (STEMI) Patients With Cardiogenic Shock at Abu Dhabi City","Inclusion Criteria:\n\n* Age more than 18.\n* STEMI complicated by cardiogenic shock.\n* Were hospitalized or treated at SSMC or SKMC for STEMI complicated by cardiogenic shock.\n* Patient admitted between January 2019 to March 2024.\n\nExclusion Criteria:\n\n* Age less than 18.\n* Shock patient not related to Myocardial infarction.\n* NSTEMI-related cardiogenic shock.\n* Patients who were not treated at SSMC or SKMC for the STEMI complicated by cardiogenic shock.\n* Patient not admitted between January 2019 to March 2024.",{"count":137,"type":19},400,"A retrospective study on the clinical characteristics and treatment outcomes of patients admitted with ST-elevation Myocardial Infarction (STEMI) complicated with cardiogenic shock (CS) during admission or CS development during their hospital stay for two tertiary hospitals in Abu Dhabi, UAE, from 2020-2024.",[140,141],"ST Elevation Myocardial Infarction","Cardiogenic Shock",[143,141,144,145],"STEMI","Morbidity","Mortality","2025-02-13",{"date":148,"type":52},"2025-02-17",{"date":150,"type":52},"2024-07-01",{"date":152,"type":19},"2025-05-30",{"name":58,"class":59},2,""]